With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1293-65-8,1,1′-Dibromoferrocene,as a common compound, the synthetic route is as follows.,1293-65-8
1 ,1′-Dibromoferrocene (0.67 g, 1.97 mmol) in anhydrous tetrahydrofuran (THF) (30 ml) was placed in a reaction vessel and cooled to -78 0C using a dry ice and acetone mixture, ?-butyl lithium (0.94 ml, 2.36 mmol) was added under inert conditions thereto and the contents of the reaction vessel kept stirred for approximately 1 hour while cold zinc chloride (2.16 ml, 2.16 mmol) was added. Tetrakis(triphenylphosphine)palladiumO (50 mg) and 4,5- dichlorophthalonitrile (0.5 g, 1.97 mmol) were then added. The contents of the reaction vessel were allowed to warm to room temperature and were kept stirred for approximately 2 hours before heating to approximately 90 C for 12 hours. Thereafter, water (20 ml) was added and extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate and reduced to dryness under reduced pressure to obtain a crude product. The crude product was placed on alumina and eluted with diethyl ether ; petroleum spirit (55:45) to yield red crystals.
The synthetic route of 1293-65-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; CORUS UK LIMITED; HOLLIMAN, Peter; RUGEN-HANKEY, Sarah; WO2010/136178; (2010); A1;,
Iron Catalysis in Organic Synthesis | Chemical Reviews
Iron Catalysis in Organic Synthesis: A Critical Assessment of What It Takes To Make This Base Metal a Multitasking Champion